With Rare Exceptions, Plans Stick With Generics for Epilepsy With Chart: Current Market Access to Epilepsy Medications

Pharmaceutical treatment for different types of epilepsy generally still relies on tried-and-true generics, despite recent efforts by drug manufacturers to introduce new branded medications into the mix, PBM insiders say.

Xcopri (cenobamate tablets) launched in May for the treatment of partial-onset seizures in adults. According to manufacturer SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., clinical trials have shown “significant reductions in seizure frequency compared to placebo at all doses studied, and as many as one in five patients achieved zero seizures during the maintenance phase.”

© 2025 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

September 26

News Briefs: Sanders Touts PBM Promise in Pushing for Wegovy, Ozempic Price Cut

READ MORE
republican-and-democratic-party
September 26

Would Red or Blue Election Wins Be Better for PBMs? It’s a Tossup

READ MORE
pharmacist
September 26

Satisfaction With PBM Industry Dips to Record Low in 2024

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today